帕博西尼治疗晚期乳腺癌4年期间发生进行性多灶性白质脑病，患者有滤泡性淋巴瘤病史。
Progressive multifocal leukoencephalopathy during 4 years of Palbociclib for advanced breast cancer with a history of follicular lymphoma patient.
作者信息
Koyamada Ryosuke, Nishihara Mariko, Masaki Tetsuhiro, Shimada Tomohito, Ishikawa Kazuhiro, Hashimoto Jun, Mori Nobuyoshi, Namai Asami, Yokoo Hideaki, Takahashi Kenta, Suzuki Tadaki, Nakamichi Kazuo, Mori Shinichiro
机构信息
Department of Hematology, St. Luke's International Hospital, Tokyo, Japan.
Department of Hematology, Yokosuka Kyosai Hospital, Yokosuka, Japan.
出版信息
J Neurovirol. 2025 Apr;31(2):191-195. doi: 10.1007/s13365-025-01255-w. Epub 2025 Apr 21.
A 67-year-old woman with a history of follicular lymphoma and recurrent breast cancer with multiple metastasis developed PML during receiving fluvestrant plus palbociclib. Rituximab and bendamustine had finished 6.5 years ago. Discontinuing palbociclib and using mirtazapine, she is alive a year after diagnosis of PML. It is rare for PML to be diagnosed long after the last dose of rituximab and bendamustine. We will discuss the possible involvement of palbociclib in the course of PML.
一名67岁女性，有滤泡性淋巴瘤病史，复发性乳腺癌伴多处转移，在接受氟维司群加帕博西尼治疗期间发生进行性多灶性白质脑病（PML）。利妥昔单抗和苯达莫司汀已于6.5年前停用。停用帕博西尼并使用米氮平后，她在被诊断为PML一年后仍然存活。在最后一剂利妥昔单抗和苯达莫司汀后很长时间才诊断出PML的情况很罕见。我们将讨论帕博西尼在PML病程中可能的作用。
Zotero 插件